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Abstract High BMI is a well-known risk factor for the
development and recurrence of several solid tumours,
including CRC. Obesity is associated with increased levels
of vascular endothelial growth factor (VEGF). Bev-
acizumab is the main targeted therapy for inhibiting tumour
angiogenesis by blocking the VEGF/VEGF receptor path-
way. Elevated VEGF in obese patients might provoke
resistance to anti-VEGF therapy. We evaluated the efficacy
of bevacizumab on TTP among mCRC patients through
stratifying them according to their BMI. Patients with
mCRC who had been treated with fluoropyrimidine-based
combination chemotherapy with bevacizumab were inclu-
ded in the study. Patients were assigned according to their
BMI before initiation of therapy (group A: BMI\ 25 kg/m2,
group B: BMI C 25 kg/m2). Multivariate analysis was per-
formed to evaluate the risk of tumour progression. Between
April 2007 and June 2011, 80 patients were treated with
chemotherapy and bevacizumab as first-line therapy (n = 37
for group A, n = 43 for group B). Tumours in 56.3 % of the
patients in group A (n = 21) and 76.3 % of the patients in
group B (n = 33) progressed during a median 10-months
(3–57 months) follow-up. The median TTP was 11.7 months
in the group A and 6 months in the group B (p = 0.004). In a
multivariate analysis, high BMI (C25 kg/m2) was associated
with significantly shorter TTP (p = 0.01; HR: 4.37). High
BMI among mCRC patients treated with bevacizumab is
associated with shorter TTP. Further study in larger dat-
abases is warranted for confirming the negative prognostic
effect of obesity during treatment with anti-VEGF agents.
Keywords Colorectal cancer  Body mass index 
Bevacizumab  Time to progression
Introduction
In recent decades, the prevalence of obesity has increased
worldwide in all age groups [1]. Increasing epidemiologi-
cal evidence has demonstrated that obesity is associated
with an increased risk of cancer, especially colon cancer
[2–4]. Several factors, such as insulin resistance, increased
levels of leptin, plasminogen activator inhibitor-1, endog-
enous sex steroids, decreased levels of adiponectin, and
chronic inflammation, are involved in carcinogenesis and
cancer progression [5].
However, a few studies that have investigated the
influence of BMI on the outcomes of colon cancer
patients have reported inconsistent findings [6–11].
Despite support for the importance of obesity and meta-
bolic syndrome as risk factors for the development of
colorectal cancer, data are equivocal for the effects on
colorectal cancer progression and outcome [6–8]. Several
studies have reported decreased survival and increased
recurrence in patients with insulin resistance or high BMI
[7–9], whereas other studies have not [6, 10, 11].
Although high BMI was associated with better median OS
in the CAIRO study, CAIRO2 study did not show this
association [11]. Consequently, testing the role of BMI in
patients receiving targeted therapy is an actual subject of
research.
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Bevacizumab is a humanised monoclonal antibody
(mAb) against vascular endothelial growth factor (VEGF),
which is the major mediator of angiogenesis. Activation of
the VEGF/VEGF receptor axis triggers multiple signalling
networks responsible for endothelial cell survival, mito-
genesis, migration, and differentiation [12]. Elevated serum
VEGF levels have been observed in overweight or obese
patients [13, 14]. The BMI of patients with metastatic CRC
at treatment initiation predicts treatment outcomes. Guiu
et al. [15] reported that high visceral fat area (VFA)
measured by computed tomography independently pre-
dicted poorer outcome in a retrospective series of patients
given first-line bevacizumab-based therapy for metastatic
colon cancer.
Although not all patients diagnosed with metastatic
CRC benefit from anti-VEGF antibody treatment, there are
currently no biomarkers available to predict the efficacy of
anti-angiogenic therapies. VEGF plays an important role as
an endothelial mitogen in tumour angiogenesis, and
increased levels of VEGF may contribute to poorer out-
comes in cancer in obese subjects [16]. Thus, BMI may be
a prognostic factor for poor outcomes in metastatic CRC
patients receiving bevacizumab-based treatment. On the
other hand, standard bevacizumab dose may be question-
able for obese patients. We performed a study of the
associations between BMI and clinical outcomes in con-
secutive patients administered bevacizumab-based treat-
ments for metastatic CRC.
Patients and methods
Eligible patients
From April 2007 to June 2011, 80 consecutive patients
with metastatic colorectal adenocarcinoma treated with
fluoropyrimidine-based combination chemotherapy plus
bevacizumab at the Institute of Oncology, Istanbul Uni-
versity (Istanbul, Turkey), were included in the study.
Patients, age between 18 and 80 years old with histologi-
cally confirmed locally advanced or metastatic CRC, were
determined. Those with one or more unidimensionally
measurable lesions, who were not amenable to curative
resection, with an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, no prior history of
cancer (except basal cell carcinoma or carcinoma in situ of
the cervix), adequate bone marrow (white absolute neu-
trophil count, C1,500/mm3, platelet count C100,000/mm3)
and liver function (total bilirubin B1.5 mg/dl and alanine
and aspartate transaminase levels \5 X upper limit of
normal), and a life expectancy of longer than 3 months
were included. Patients who received bevacizumab as a
second-line treatment were also included. Patients received
one of the following treatment regimens: simplified
LV5FU2 (leucovorin 400 mg/m2, followed by 5-fluoro-
uracil as a 400 mg/m2 bolus and a 2,400 mg/m2 infusion
over 46 h), modified FOLFOX regimen (simplified
LV5FU2 regimen plus oxaliplatin 85 mg/m2), FOLFIRI
(simplified LV5FU2 regimen plus irinotecan 180 mg/m2
every 2 weeks), XELOX (capecitabine 1,000 mg/m2,
b.i.d., p.o., days 1–14 plus oxaliplatin 130 mg/m2 every
3 weeks), or XELIRI (capecitabine 1,000 mg/m2, b.i.d.,
p.o., days 1–14 plus irinotecan 240 mg/m2 every 3 weeks).
Bevacizumab was administered at a dosage of 5 mg/kg
every 2 weeks or 7.5 mg/kg every 3 weeks. The dosages of
chemotherapeutic agents were determined according to the
measured body surface area (BSA); however, for patients
with BSA over 2 m2, dosages were adjusted according to
2 m2. For bevacizumab, no dosing reduction was accom-
plished, i.e. patients received the exact planned dose for
their actual weight. All of the patients had unresectable
liver metastases associated with primary tumours at the
initial consultation. Patients who underwent hepatic
resection and local ablative therapies, chemo-embolisation,
or radio-embolisation were excluded. Pregnant or breast-
feeding women were excluded. Other key exclusion criteria
were as follows: clinically significant cardiovascular dis-
ease; exclusive bone metastasis; use of full-dose anti-
coagulants or thrombolytics; known CNS metastases;
serious non-healing wound, ulcer, clinically significant
bleeding diathesis, or coagulopathy.
Tumour response was evaluated using a computed
tomography scan or magnetic resonance imaging depend-
ing on which imaging methods were used at baseline.
Tumour responses and progression were determined every
8 weeks using the Response Evaluation Criteria in Solid
Tumours [17] by the investigators and classified as follows:
complete response (CR), partial response (PR), stable dis-
ease (SD), or progressive disease (PD). The tumour
response after 2 months of chemotherapy was used for
statistical analysis. Patients with either CR or PR were
classified as responders, and patients with SD or PD were
considered non-responders. This retrospective study was
approved by our institutional review board.
Baseline demographic, clinical, and laboratory data,
including age, gender, performance status, tumour marker
levels, K-ras mutation status, and treatment details, were
collected retrospectively for all patients using uniform
database templates to ensure consistent data collection.
Statistical analyses
SPSS version 16.0 (SPSS Inc., Chicago, IL) was used for
the statistical analyses. The follow-up duration was cal-
culated from the date of the first bevacizumab adminis-
tration to the date of death or last follow-up visit. The time
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to progression (TTP) was calculated as the period from the
initiation of treatment to the first observation of disease
progression or to disease-specific death. The influence of
putative prognostic factors on the progression of disease
was evaluated by univariate analysis. Fifty-four (67.5 %)
of the 80 patients with complete clinical and pathological
data experienced disease progression during follow-up.
TTP was evaluated with Mann–Whitney U test. Descrip-
tive, univariate, and multivariate analyses were performed
for those 54 patients with progression. Univariate Cox
proportional-hazards models of all the potential baseline
predictors were built to compute the hazard ratios (HR)
with 95 % confidence intervals (CI). A multivariable bin-
ary logistic regression analysis was accomplished using a
stepwise algorithm including age (years; \60 vs. C60),
BMI (\25 vs. C25), primary tumour status (intact versus
non-intact), type of chemotherapy regimens (irinotecan
based versus oxaliplatin based), K-ras mutational status
(wild type versus mutated), carcinoembryonic antigen
(CEA) level (median,\28 vs. C28), and number of disease
sites. For BMI, patients were categorised as underweight/
normal weight (BMI \ 25 kg/m2), or overweight/obese
(BMI C 25 kg/m2). All P values were two-sided.
Results
At the time of the final follow-up, 4 (5 %) within 54
patients (67.5 %) who exhibited tumour progression were
deceased due to disease-related factors. Remaining 26
(32.5 %) patients had no evidence of progression during
the last evaluation.
The clinical and demographic data of 54 metastatic CRC
patients who had disease progression during chemotherapy
with bevacizumab were summarised in Table 1 and 2. The
median age for these patients was 60.5 years (range
34–78); 59.3 % (n = 32) of the patients were male, and
40.7 % (n = 22) were female. Distant metastasis was
present in 63 % of the patients at the time of diagnosis.
Adjuvant chemotherapy was administered in 20 (37.0 %)
patients. The primary location of the malignancy was sig-
moid colon and recto-sigmoid junction in 18 patients
(33.4 %), rectum in 17 patients (31.5 %), right colon-cae-
cum in 14 patients (25.8 %), left colon in 3 patients
(5.6 %), and transverse colon in two patients (3.7 %).
Twenty-nine (53.7 %) patients had K-ras mutations, and 25
(46.3 %) patients had no mutations.
All patients received bevacizumab-containing chemo-
therapy regimens as first-line therapy. The median number
of treatment cycles was 10 (range 2–32). Oxaliplatin-based
chemotherapy was administered to 19 patients (35.2 %),
and irinotecan-based chemotherapy was administered to 35
patients (64.8 %) in combination with bevacizumab.
Height and weight were recorded before initiation of
bevacizumab and used to assign patients to group A
(BMI \ 25 kg/m2) and group B (BMI C 25 kg/m2).
Baseline characteristics (age, gender, number of metastatic
locations, CEA, and CA 19–9 levels and K-ras mutation
status) and treatment details such as number of cycles,
resection status of the primary tumour, type of chemo-
therapeutic agent combined with bevacizumab, and
response to treatment of all patients are represented in
Tables 1 and 2. Twenty-one (56.3 %) of 37 patients in
group A and 33 (76.7 %) of 43 patients in group B pro-
gressed during a median of 10-months follow-up (range
3–57 months).
For 54 patients who had disease progression and com-
plete clinical data concerning the variables included in
univariate analysis, the influence of the 7 variables on TTP
was evaluated with Mann–Whitney U test. Finally through
grouping TTP according to the median value, the effect of
these variables on TTP was analysed with binary logistic
regression model. In univariate analysis, BMI C 25
(p = 0.004) and higher number of metastatic sites
(p = 0.032) were associated with poor TTP. The median
TTP was 11.7 months in the group A and 6 months in the
group B (p = 0.004).
A multivariate logistic regression model for TTP was
constructed that included age, BMI, serum CEA level,
K-ras mutational status, primary tumour status (intact or
non-intact), chemotherapy regimens, and number of dis-
ease sites. The results are displayed in Table 3. The only
independent prognostic factor for TTP was BMI (p = 0.01;
OR, 4.37; 95 % CI, 1.34–14.78) for patients with meta-
static CRC treated with bevacizumab.
Discussion
Recent phase III trials have shown that adding bevacizumab
to a first-line conventional chemotherapeutic regimen
improved progression-free survival and overall survival in
patients with metastatic CRC [18, 19]. Despite extensive
investigation, there are no validated predictive biomarkers of
the efficacy of VEGF-targeted therapies, such as bev-
acizumab. Obese animal models have been shown to be
resistant to anti-VEGF treatment [20], which suggests that
increased amounts of visceral fat may be associated with
high VEGF levels and resistance to bevacizumab-based
regimens in patients with metastatic CRC [15].
In the present study, the median TTP was 11.7 months in
the BMI \ 25 group and 6 months in the BMI C 25 group
(p = 0.004). In addition, the multivariate analysis indicated
that increased BMI was the most important predictor of
progression in the patients receiving the bevacizumab
treatment. Evidence accumulated over the past decade has
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clearly established excess body fat as a risk factor for colo-
rectal cancer. Specifically, risk increases with increasing
BMI in a sex-(greater risk for men) and site-specific (greater
occurrence in the colon versus rectum) manner [21]. A
number of plausible biological mechanisms are responsible
for the observed associations, including increased insulin
resistance, increased availability of insulin-like growth fac-
tor (IGF)-1 (which is mitogenic, proapoptotic, and proangi-
ogenic and increases cell motility), and altered adipokine
metabolism. These alterations result in increased leptin,
which is mitogenic, anti-apoptotic, and proangiogenic, and
decreased adiponectin, which is also anti-angiogenic and
anti-inflammatory [5, 22].
Obesity is a well-established risk factor for developing
CRC [23] and has been associated with increased mortality
from colon cancer [24, 25]. Obesity is also associated with
a sedentary lifestyle and typical Western diet, which are
associated with increased rates of cancer recurrence and
death among patients with a history of curative surgical
resection for CRC [7, 26, 27]. The patho-physiology is not
completely understood but may involve adipose tissue
production of adipokines and proangiogenic cytokines,
such as VEGF, which may promote cancer growth and
dysregulated angiogenesis [13]. All of the studies evalu-
ating the association between body mass and mortality
caused by CRC have focused on patients at the time of
diagnosis of localised diseases. To our knowledge, only
one trial [15] has analysed the influence of obesity on the
prognosis of metastatic CRC patients receiving VEGF-
targeted therapy.
Obesity is strongly associated with changes in the
physiological function of adipose tissue and may cause
insulin resistance, chronic inflammation, and altered
secretion of adipokines. Adipose tissue is now recognised
to function as an endocrine and paracrine organ that
releases cytokine-like polypeptides responsible for wide-
spread biological effects [28, 29]. In particular, adipocytes
produce insulin-like growth factor and multiple angiogenic
factors, including VEGF and leptin [30]. Leptin exerts
direct angiogenic effects [29, 30], upregulates VEGF
mRNA expression [31], and induces VEGF-mediated
angiogenesis by colonic epithelial cells [32]. Inflammatory
cells infiltrating the adipose tissue and adipose stromal
cells also contribute to VEGF production [30, 33]. Elevated
serum VEGF levels have been reported in overweight and
obese patients [13, 14].
Visceral fat accumulation has been shown to be asso-
ciated with colorectal adenoma formation [34], colon car-
cinogenesis [35], and increased risk for developing colon
cancer. The amount of visceral fat independently predicts
disease-free survival in patients with resectable CRC [8].
The data strongly suggest that visceral fat may induce the
accumulation of protumorigenic factors and be associated
with poorer outcomes in patients with CRC.
The role of bevacizumab-based therapy (in combina-
tion with conventional chemotherapy) has been estab-
lished as an option for metastatic CRC. Until now, no
predictive biomarker has been available to direct treat-
ment algorithms. Biomarkers are available for other
mechanism-based therapies in metastatic CRC, including
K-ras status and cetuximab therapy, in which measure-
ment of the predictive biomarker clearly discriminates the
subsequent treatment response. While using BMI as a
‘lifestyle biomarker’ may appear to be unconventional
(compared with traditional gene or protein biomarkers),
Table 1 Basal characteristics of metastatic CRC patients who pro-





BMI \ 25 21 (38.9) Median (years) 60.5
BMI C 25 33 (61.1) (range) (34–78)
Sex CEA
Male 32 (59.3) Median (ng/ml) 5
Female 22 (40.7) (range) (0.8–20,300)
KRAS analysis CA 19–9
Mutant 29 (53.7) Median (ng/ml) 39.5





BMI body mass index, CEA carcinoembryonic antigen, CA 19–9
carbohydrate antigen 19–9
Table 2 Treatment details of patients with disease progression
Characteristic n = 54 (100 %)
Primary tumour resection
Yes 45 (83.3 %)





Oxaliplatin 19 (35.2 %)
Irinotecan 35 (64.8 %)
Response to bevacizumab-based therapy
CR ? PR 23 (42.6 %)
SD ? PD 31 (57.4 %)
CR complete response, PR partial response, SD stable disease, PD
progressive disease
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lifestyle is used as a predictive factor for treatment
response of other cancer types; smoking status is used for
directing anti-epidermal growth factor receptor (EGFR)
therapy (erlotinib) in non-small cell lung cancer.
The limitations of our study include a relatively small
number of patients, limited follow-up duration, single-
centre patient recruitment, and a retrospective design. In
addition, the definition of obesity is controversial, and it is
unclear whether BMI is the most appropriate measure of
obesity. BMI and BSA are crude measures of obesity, and
VFA (visceral fat area) or SFA (subcutaneous fat area) may
be more appropriate obesity indicators. Computed tomog-
raphy can be used to accurately assess intra-abdominal fat
via measurements of SFA and VFA at the level of the
umbilicus [23]. However, in clinical practice, SFA and
VFA measurements may be difficult and expensive. BMI is
a useful, easy, and non-invasive biomarker. Moreover,
there is still a controversion among different centres about
dosing of chemotherapy for overweight patients due to the
concerns of toxicity [36]. In our study, dosage adjustment
of chemotherapeutic agents for patients with BSA over
2 m2 might have confounded the evaluation of treatment
efficacy. However, bevacizumab dosing was applied
according to the actual patient weight; thus, patients are
supposed to receive ideal planned anti-VEGF therapy.
In conclusion, our results provide the evidence that the
BMI of patients prior to initiating VEGF-targeted therapy
is a simple prognostic factor for patients with metastatic
CRC. Further studies may help determine whether the
predictive effects of high BMI are related to either a larger
distribution volume of VEGF-targeted therapies, the pro-
duction of high levels of VEGF by visceral fat, or both.
Consequently, patients with high BMIs may not benefit
from VEGF-targeted therapy or may require higher dos-
ages. If further validation studies with VEGF-targeted
therapies corroborate our results, BMI should be incorpo-
rated into clinical patient care and stratification schema for
future clinical trials. VEGF-targeted therapies should
consider physiological parameters related to the patient in
addition to pathologic parameters related to the tumour.
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